AI technology uncovers genetic factors and treatment options for Parkinson's

Researchers at the Cleveland Clinic Genome Center have used advanced artificial intelligence (AI) genetics models to identify genetic factors in Parkinson's disease progression and suggest FDA-approved drugs for potential repurposing to treat the condition. The study, published in npj Parkinson's Disease, applied a "systems biology" approach, integrating genetic, proteomic, pharmaceutical, and patient datasets with AI to uncover patterns not visible through isolated analysis. This method helped identify potential risk genes, including SNCA and LRRK2, which are linked to brain inflammation when dysregulated. Dr. Feixiong Cheng, the study leader and systems biology expert, and his team used their AI model to cross-reference Parkinson's-related genetic variants with brain-specific DNA and gene expression databases. They pinpointed how variants in noncoding DNA regions affect specific genes and, consequently, brain proteins. By combining these findings with protein interaction data, they identified potential drug targets. Next, the team explored whether existing FDA-approved drugs could be repurposed to address these genetic targets. One promising candidate was the cholesterol-lowering drug simvastatin, as electronic health records showed individuals taking it were less likely to develop Parkinson's. Other drugs, including immunosuppressive and anti-anxiety medications, also showed potential for further investigation. Dr. Cheng emphasized the urgency of finding treatments to slow or stop Parkinson's progression, given the lack of disease-modifying therapies. By repurposing approved drugs, researchers could bypass lengthy safety testing, speeding up the process of providing new options for patients. Dr. Lijun Dou highlighted how their AI-powered analyses significantly accelerated the discovery process, increasing the likelihood of finding effective solutions. The next steps involve laboratory testing of the identified drugs, including simvastatin, to evaluate their potential as treatments for Parkinson's disease.